Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B870529feee9896ca9ebcbf9f8a3d8596> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B870529feee9896ca9ebcbf9f8a3d8596 NCIT_P378 "NCI" @default.
- B870529feee9896ca9ebcbf9f8a3d8596 type Axiom @default.
- B870529feee9896ca9ebcbf9f8a3d8596 annotatedProperty IAO_0000115 @default.
- B870529feee9896ca9ebcbf9f8a3d8596 annotatedSource NCIT_C158504 @default.
- B870529feee9896ca9ebcbf9f8a3d8596 annotatedTarget "A human bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFvs): one directed again the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and another directed against the CD3 antigen expressed on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, linvoseltamab binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, leading to CTL-mediated killing of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival." @default.